FY2025 · ended Dec 31, 2025 · Revenue $130,000, +132.1% YoY · Filed Mar 25, 2026
Serina Therapeutics, Inc. (SER) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $130,000 and a net loss of $19.2 million. Free cash flow was -$18.0 million. As of Jun 30, 2026 it held $23.0 million in cash and investments and $122,000 in total debt.
Revenue (TTM)
$0
-100.0% vs year-ago TTM
Net income (TTM)
$-21.18M
-68.2% vs year-ago TTM
Operating cash flow (TTM)
$-21.14M
-35.3% vs year-ago TTM
Free cash flow (TTM)
$-21.20M
-35.2% vs year-ago TTM
EPS (TTM)
$-1.94
-44.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
12.31M
+24.0% vs prior year
Net cash
$22.90M
as of Jun 30, 2026
Operating margin
-18478.5%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SER (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- AL
- Headquarters
- Huntsville, AL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1708599
- Former names
- AgeX Therapeutics, Inc. (until Apr 1, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $130,000 | $56,000 | $3.2M | $34,000 | $144,000 |
| Operating income | -$24.0M | -$17.0M | -$3.1M | -$7.0M | -$7.9M |
| Net income | -$19.2M | -$11.1M | $5.3M | -$10.5M | -$8.7M |
| Diluted EPS | -$1.91 | -$1.51 | $0.73 | — | — |
| Operating cash flow | -$18.0M | -$17.1M | -$2.5M | -$5.9M | -$7.9M |
| Free cash flow | -$18.0M | -$17.2M | — | — | — |
| Total assets | $7.0M | $6.7M | $9.0M | $3.2M | $3.2M |
| Total liabilities | $7.0M | $6.2M | $4.9M | $20.6M | $15.0M |
| Stockholders' equity | -$37,000 | $641,000 | -$32.3M | -$17.2M | -$11.8M |
| Cash and investments | $3.1M | $3.7M | $7.6M | $645,000 | $584,000 |
| Total debt | $377,000 | $461,000 | — | $18.1M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 9, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 27, 2026 | Aug 21, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 23, 2026 | Jul 19, 2026 |
All 519 Serina Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.